Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

EXICURE HITRON (019490) Stock Price & Analysis

019490 Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
KRW 41.34B
Enterprise Value
KRW 63.91B
Total Cash (Recent Filing)
KRW 1.93B
Total Debt (Recent Filing)
KRW 5.24B
Price to Earnings (P/E)
―
Beta
-0.02
Next Earnings
Nov 13, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Moderate Latest Leverage

The latest balance-sheet leverage is more moderate than in prior peak-leverage years, providing some relative financial stability. This may preserve more flexibility for operations and development than the company had during periods of extreme leverage, although continued losses remain a constraint.

Proprietary Therapeutic Platform

A proprietary nucleic-acid platform gives the company a defined scientific foundation in immune-mediated and oncology-related drug development. If its candidates advance, this capability could support differentiated products, development partnerships, and longer-term strategic value.

Losses Narrowed From 2024

The reduction in losses from the exceptionally weak 2024 level indicates some improvement in reported profitability, even though margins remain negative. Sustaining further improvement would reduce the pace of financial deterioration and could eventually support a more viable operating model.

Bears Say

Persistent Unprofitability

Consistently negative gross, operating, and net profit show that the business has not yet demonstrated a sustainable economic model. Continued negative margins can consume capital, limit reinvestment capacity, and make future growth dependent on funding rather than internally generated earnings.

Ongoing Cash Burn

Recurring negative operating and free cash flow indicates that reported activities are not currently self-funding. Persistent cash burn can increase reliance on external capital or balance-sheet flexibility, potentially constraining research investment and weakening resilience if losses continue.

Revenue Contraction And Volatility

The sharp 2025 revenue decline following only a modest prior-year increase suggests weak and inconsistent commercial traction. Without a stable revenue base, fixed development and operating costs are harder to absorb, increasing the likelihood that profitability and cash generation remain under pressure.

019490 FAQ

What is EXICURE HITRON’s market cap?
EXICURE HITRON’s market cap is ₩41.34B.
When is EXICURE HITRON’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were EXICURE HITRON’s earnings last quarter?
EXICURE HITRON released its earnings results on Aug 14, 2026. The company reported -$45.141 earnings per share for the quarter.
Is EXICURE HITRON overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does EXICURE HITRON pay dividends?
EXICURE HITRON does not currently pay dividends.
What is EXICURE HITRON’s EPS estimate?
EXICURE HITRON’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EXICURE HITRON have?
EXICURE HITRON has 76,432,270 shares outstanding.
What happened to EXICURE HITRON’s price movement after its last earnings report?
EXICURE HITRON reported an EPS of -$45.141 in its last earnings report. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of EXICURE HITRON?
Currently, no hedge funds are holding shares in KR:019490
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology